COMBINING TROP2-DIRECTED CAR-NK CELLS WITH HIF2A INHIBITION FOR THE IMMUNOTHERAPY OF PANCREATIC CANCER

The Univeristy Of Texas M.D. Anderson Cancer Center

Investigators